Pancreatic Cell News 8.10 March 14, 2017 | |
| |
TOP STORYScientists report that centromere protein A (CENP-A), which is required for chromosome segregation during the M-phase, is necessary for adaptive β cell proliferation. [Cell Metab] Abstract | Press Release | Graphical Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)DIABETES & PANCREATITISMicroRNA 21 Targets BCL2 mRNA to Increase Apoptosis in Rat and Human Beta Cells The authors sought to define the context of beta cell microRNA (miR)-21 upregulation in type 1 diabetes and the phenotype of beta cell miR-21 overexpression through target identification. Beta cell miR-21 was increased in in vivo models of type 1 diabetes and cytokine-treated cells/islets. In silico prediction tools identified the antiapoptotic mRNA B cell lymphoma 2 (BCL2) as a conserved miR-21 target. [Diabetologia] Abstract Scientists explored the roles of GAD and produce γ-aminobutyric acid (GABA) in alpha cell proliferation in conditions corresponding to type 1 diabetes in a mouse model and in vitro. STZ injection substantially decreased levels of GAD, GABA and insulin in pancreatic beta cells 12 hours after injection; this was followed by an upsurge of phosphorylated mechanistic target of rapamycin in the alpha cells at day one, and a significant increase in alpha cell mass at day three. [Diabetologia] Abstract Little is known about how cells handle excess fuels to avoid toxicity. The authors sought to determine which among the candidate pathways and coupling factors best correlates with glucose-stimulated insulin secretion (GSIS), define the fate of glucose in the β-cell, and identify pathways possibly involved in excess-fuel detoxification. Using targeted metabolomics in INS-1 cells, they found that several metabolites correlated well with GSIS, in particular, some Krebs cycle intermediates, malonyl-CoA, and lower ADP levels. [J Biol Chem] Abstract | Full Article Spatial and Quantitative Datasets of the Pancreatic β-Cell Mass Distribution in Lean and Obese Mice Investigators present ex vivo optical tomographic data sets of the full β-cell mass distribution in cohorts of obese ob/ob mice and their lean controls, together with information about individual islet β-cell volumes, their three-dimensional coordinates and shape throughout the volume of the pancreas between four and 52 weeks of age. [Sci Data] Full Article | Press Release PANCREATIC CANCERThe authors report that genetic modification of primary human pancreatic cells leads to development of lesions resembling native human pancreatic intraepithelial neoplasia. Primary human pancreas duct cells harboring oncogenic KRAS and induced mutations in CDKN2A, SMAD4 and TP53 expand in vitro as epithelial spheres. [Nat Commun] Full Article | Press Release Variability in Statin-Induced Changes in Gene Expression Profiles of Pancreatic Cancer Scientists aimed to identify the biological pathways affected by individual statins in an in vitro model of human pancreatic cancer. Large differences in the gene transcription profiles of pancreatic cancer cells exposed to various statins were observed; cerivastatin, pitavastatin, and simvastatin being the most efficient modulators of expression of genes involved namely in the mevalonate pathway, cell cycle regulation, DNA replication, apoptosis and cytoskeleton signaling. [Sci Rep] Full Article Researchers found that family with sequence similarity 83, member A (FAM83A) is significantly overexpressed and associated with poorer overall survival and disease-free survival in pancreatic cancer. Overexpression of FAM83A markedly promoted, whereas inhibition of FAM83A decreased, cancer stem cell-like traits and chemoresistance both in vitro and in an in vivo mouse model of pancreatic cancer. [Oncogenesis] Full Article Scientists used the PANC-1 and MIA PaCa-2 cell lines to specifically assess the role of transient receptor potential melastatin 7 (TRPM7) in cell invasion and matrix metalloproteinase secretion. They showed that TRPM7 regulates Mg2+ homeostasis and constitutive cation entry in both pancreatic ductal adenocarcinoma cell lines. [Neoplasia] Full Article Researchers confirm that miR-200a attenuates TGF-β1-induced pancreatic stellate cells activation and extracellular matrix formation. They found that TGF-β1 induces activation and extracellular matrix formation in pancreatic stellate cells (PSCs), and the effects are blocked by the inhibitor of PI3K. They identified that miR-200a is down-regulated in TGF-β1-activated PSCs, and up-regulation of miR-200a inhibits PSCs activation induced by TGF-β1. [Mol Cell Biochem] Abstract | |
| |
REVIEWSAcinar Cell Plasticity and Development of Pancreatic Ductal Adenocarcinoma The author discusses the critical determinants of acinar cell plasticity, in addition to the intracellular and extracellular signaling events that drive acinar cell metaplasia and their contribution to development of pancreatic ductal adenocarcinoma. [Nat Rev Gastroenterol Hepatol] Abstract Scientists provide an overview of the interaction between pancreatic ductal adenocarcinoma (PDAC) and hyaluronan, the properties of 4-methylumbelliferone as a suppressor of the synthesis of hyaluronan, and the perspectives of PDAC treatment targeting hyaluronan. [Int J Mol Sci] Full Article Role and Impact of the Extracellular Matrix on Integrin-Mediated Pancreatic β-Cell Functions Researchers present an update on the major components of the pancreatic extracellular matrix, their role during integrin-mediated cell-matrix adhesions and how they are affected during diabetes. [Biol Cell] Abstract Visit our reviews page to see a complete list of reviews in the pancreatic cell research field. | |
| |
INDUSTRY NEWSMerck and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review three New Drug Applications for medicines containing ertugliflozin, an investigational SGLT2 inhibitor in development to help improve glycemic control in adults with type 2 diabetes: one for monotherapy, one for the fixed-dose combination of ertugliflozin and JANUVIA®, and one for the fixed-dose combination of ertugliflozin and metformin. [Merck & Co., Inc.] Press Release Sanofi and Voluntis announced a non-exclusive agreement to deliver digital insulin titration solutions, featuring a mobile phone application designed to help improve decision-making and self-management of type 2 diabetes for people treated with basal insulin. The application will also enable remote monitoring by health care teams. [Voluntis] Press Release Major Pharmaceutical Companies Collaborate in Groundbreaking NCCN Project The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program has funded three studies in its first multi-industry collaborative research project in which Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company are collaborating with NCCN® to study combination therapeutic agents in lung cancer and head and neck cancers. [National Comprehensive Cancer Network] Press Release | |
| |
POLICY NEWSU.K. Scientists Prepare for Impending Break with European Union For months after the United Kingdom (U.K.) voted last June to leave the European Union (EU), many British scientists clung to hopes of a “soft Brexit,” which would not cut them off from EU funding and collaborators. But Prime Minister Theresa May, who is expected to trigger the two-year process of exiting the European Union, has signaled the break will be sharp. U.K. researchers are now facing up to the prospect that they won’t be able to apply for EU funding or easily recruit students and colleagues from the rest of Europe. [ScienceInsider] Editorial Canada’s New Genetic Privacy Law Is Causing Huge Headaches for Justin Trudeau A vote in Canada’s Parliament to approve a genetic privacy bill is creating a self-inflicted political headache for Prime Minister Justin Trudeau’s Liberal government—and could result in a relatively rare and unusual court case. [ScienceInsider] Editorial Physician with Drug-Industry Ties Is Trump’s FDA Pick President Donald Trump has nominated Scott Gottlieb — a conservative pundit, physician and venture capitalist — to head the US Food and Drug Administration (FDA). [Nature News] Editorial
| |
EVENTSNEW Cell Culture World Congress Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Fellows – Diabetes Research (Icahn School of Medicine at Mount Sinai) Senior Scientist – Pancreatic Cell Research (STEMCELL Technologies Inc.) Research Positions – Mouse Genetics, Diabetes and Reprogramming (Inserm) Postdoctoral Fellow – Drug Safety and Metabolism (AstraZeneca) Postdoctoral Associate – Human Pancreatic Stem Cells (Nestlé) Postdoctoral Fellowship – Beta Cell Regeneration (Helmholtz Zentrum München) Lecturer/Senior Lecturer – Pancreatic Cancer (Queen Mary University of London) Postdoctoral Fellows – Cancer Epigenetics (Baylor Scott & White Research Institute) Postdoctoral Position – Pancreatic Cancer (Cold Spring Harbor Laboratory) Postdoctoral Fellow – Islet Function/Regeneration (Toronto General Research Institute) Postdoctoral Associate – Pancreatic Cancer (University of Miami) Principle Scientist – Translational Development (Celgene Corporation) Assistant Professor – Molecular Therapeutics (Dartmouth College/Geisel School of Medicine) Vice President – Pancreatic Cancer Disease Lead (Celgene Corporation) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Pancreatic Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|
Home Pancreatic Cell News Volume 8.10 | Mar 14 2017